Knee cartilage that wears away normally never grows back — but a stem-cell therapy used in South Korea since 2012, CARTISTEM®, is now being tested in a U.S. Phase 3 trial that enrolled its first patient in July 2026.
For patients with knee osteoarthritis, that timing matters. Cartilage has almost no blood supply, so once it wears away it does not repair itself; most current treatments aim to ease pain rather than rebuild tissue.
CARTISTEM®, made from donated umbilical cord blood stem cells, is applied directly into a cartilage defect during a single operation, with the goal of filling the defect with new cartilage-like tissue. More than 36,000 patients have received it in Korea, according to the manufacturer.
“CARTISTEM gives us something we did not have before: a way to treat the cartilage defect itself, not just the symptoms,” said Yeong Seok Lee, M.D., Ph.D., an orthopedic surgeon at St. Luke’s Hospital in Seoul. “For the right patient, it can be a meaningful step before a knee replacement.”
Those words capture why regulators on three continents are now watching: the therapy shifts the target from symptom relief to the damaged tissue itself.

Korea approves CARTISTEM; U.S. trial pending
- CARTISTEM® is already approved and widely used in South Korea, but it is not FDA-approved — Americans cannot get it commercially in the United States.
- In Korea’s randomized trial, 97.7% of treated patients showed cartilage improvement on follow-up arthroscopy at 48 weeks, versus 71.7% with the standard microfracture procedure.
- Recovery is demanding: roughly two to three months on crutches and about a year of rehabilitation.
2012: Korea approves a cord-blood cartilage therapy
South Korea approved CARTISTEM® in 2012. The product’s mechanism of action — in plain terms, how it is supposed to work — relies on mesenchymal stem cells harvested from donated umbilical cord blood. Because these donor cells are placed into the defect during surgery, nothing is harvested from the patient’s own body.
The procedure happens in one operating-room session. The surgeon first confirms the size and location of the cartilage defect arthroscopically, then makes small holes in the damaged area under anesthesia delivered by a full-time anesthesiologist, and finally applies the donor stem cells into the defect.
The pivotal Korean evidence comes from a Phase 3 trial published in the Orthopaedic Journal of Sports Medicine. In it, 114 patients with large, full-thickness cartilage defects were randomly assigned to CARTISTEM or to microfracture, a standard cartilage procedure.
| Trial | Patients | Comparator | Key result |
|---|---|---|---|
| Korea, Phase 3 (48 weeks) | 114 | Microfracture surgery | Cartilage improved ≥1 grade in 97.7% vs 71.7% on second-look arthroscopy |
| Japan, Phase 3 (52 weeks) | 130 at 13 hospitals | Hyaluronic acid injections | Both co-primary endpoints met, per the manufacturer (May 2026) |
| United States, Phase 3 (under way) | 300 planned, ~70 sites | Surgical debridement | First patient treated July 2026; results not yet available |
During extended follow-up of three to five years, the Korean CARTISTEM group also reported better pain and knee function than the microfracture group, suggesting the benefit held up over time.
May 2026: Japan’s Phase 3 clears both endpoints
In May 2026, the manufacturer reported results from a Japanese Phase 3 trial of 130 patients with moderate to severe knee osteoarthritis at 13 hospitals, comparing CARTISTEM with hyaluronic acid injections over 52 weeks.
The company said the trial met both co-primary endpoints: a patient-reported pain and function score, and cartilage repair confirmed by second-look arthroscopy. It also reported that all secondary endpoints were met. An application for approval in Japan is planned by the end of 2026, with approval targeted for 2027.
FDA clears U.S. trial for CARTISTEM
The U.S. Food and Drug Administration cleared the American trial in February 2026, and in June agreed that a single key study could support an application for approval.
The U.S. trial is randomized and double-blind. It plans to enroll 300 adults with Kellgren-Lawrence grade 2–3 arthritis at about 70 sites in the United States and Canada, comparing CARTISTEM with surgical debridement. Enrollment is expected to take about two years, followed by two years of follow-up.
Until that trial reads out, the therapy’s status in America is unchanged: CARTISTEM is not FDA-approved for commercial use.
Who qualifies — and who does not
CARTISTEM is generally considered for people with stage 2–3 knee arthritis and a defined area of deep cartilage damage, often confirmed on MRI. It is usually not suitable for severe, bone-on-bone arthritis across the whole joint, or for knees with significant misalignment that must be corrected first.
“The best results come from choosing the right candidate,” Dr. Lee said. “That starts with a careful look at the MRI and an honest conversation about the recovery. When the damage is in the right place and the patient is ready for the rehabilitation, this is a treatment I am glad to be able to offer.”
At St. Luke’s Hospital in Seoul, MRI scans are taken on site and read the same day by a full-time radiologist. Because the same orthopedic team also offers bone marrow injection and joint replacement, patients can compare options before deciding. International patients should plan on a stay of about four weeks in Seoul, the hospital says, with crutches for roughly two to three months and rehabilitation for about a year.
Contraindications & When to Consult a Doctor
- Bone-on-bone arthritis across the whole joint: generally not a candidate; joint replacement pathways should be discussed with an orthopedic surgeon.
- Significant joint misalignment: usually needs correction before any cartilage procedure is considered.
- Anyone in the U.S. seeking this therapy: it is not FDA-approved for commercial use; suitability, expected benefits, limitations, risks and alternatives should be reviewed individually with a qualified physician.
Patients in the United States can send recent X-rays or MRI images for a review from home or email the hospital’s international team; the team replies in English within three business days, and consultations are held directly in English with Dr. Lee, a Clinical Professor at Sungkyunkwan University School of Medicine (Samsung Medical Center) whose research has appeared in The American Journal of Sports Medicine and the Journal of Shoulder and Elbow Surgery.
What comes next, and when
The near-term regulatory marker is Japan: an approval application by the end of 2026, with a decision targeted for 2027. The next installment in this series, a step-by-step approach before knee replacement, is scheduled for November 24.
The setting of this story is a country whose demographics make such therapies consequential. South Korea, officially the Republic of Korea, occupies the southern half of the Korean Peninsula in East Asia and has a population of about 52 million, half of whom live in the Seoul metropolitan area, the world’s ninth most populous.
It has one of the world’s longest life expectances, yet its population is aging rapidly due to one of the world’s lowest fertility rates — a combination that puts added weight on treatments for conditions common in older knees.
The country’s rise also frames its role as a source of medical innovation. After the Korean War ended in 1953 with an armistice and both economies in ruins, South Korea recorded one of the world’s fastest rises in average GDP per capita, emerging as one of the Four Asian Tigers.
Today it is a highly developed country whose economy ranks 14th largest, and it performs well in metrics of education, human development, and innovation.
References
- Orthopaedic Journal of Sports Medicine — Korean Phase 3 randomized trial of CARTISTEM versus microfracture
- U.S. Food and Drug Administration — regulatory clearance of the U.S. Phase 3 trial (February 2026)
- Manufacturer-reported Phase 3 results, Japan (May 2026), 130 patients, 13 hospitals
- St. Luke’s Hospital, Seoul — interviews with Yeong Seok Lee, M.D., Ph.D.
This article is for general information and is not medical advice. Individual results vary.